XM does not provide services to residents of the United States of America.

Clariant cuts sales target on weak catalyst business, shares fall



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Clariant cuts sales target on weak catalyst business, shares fall</title></head><body>

Writes through to add sales outlook, details on catalysts business, share reaction and analyst comment

By Chiara Holzhaeuser and Antonis Pothitos

July 30 (Reuters) -Shares in Clariant CLN.S fell 7.5% on Tuesday after the Swiss speciality chemicals maker lowered its full-year sales forecast due to a weak performance in its catalysts unit, overshadowing a hike in its margin target.

Clariant expects its sales to be flat or grow by up to a low single-digit percentage this year. Growth in its Adsorbents & Additives unit and its Care Chemicals arm, which includes the newly acquired Lucas Meyer, is expected to compensate for uncertainties in the catalyst business, it said.

The group had originally guided for low single-digit percent sales growth in local currency.

"Investors probably didn't like the weak performance of the catalyst business and the lowered sales guidance," Kepler Cheuvreux analyst Christian Faitz said.

Sales in the catalysts division, which provides catalytic solutions for the chemical industry, fell by 18% in local currency to 222 million Swiss francs ($250.5 million) in the second quarter, hit by declines across its segments.

Clariant said the unit's volumes fell from a year earlier "due to the project nature of the business", while pricing remained stable.

While Clariant expects the overall inflationary environment to continue to ease, it said it does not anticipate a broad market recovery in the second half of the year.

"Our expectation moving forward is for raw materials (prices) to slightly sequentially increase," CEO Conrad Keijzer said during a conference call. For the whole year, raw material costs should still be 7% lower than in 2023, he added.

The company raised its 2024 core profit (EBITDA) margin forecast to around 16% from around 15% previously.

Its EBITDA margin rose to 16.4% in the first half of the year, aided by lower raw material and energy costs and a reduced impact from the closing of its Sunliquid bioethanol production in Romania.

($1 = 0.8861 Swiss francs)



Reporting by Chiara Holzhaeuser and Antonis Pothitos in Gdansk; Editing by Milla Nissi

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.